Consolidation clinical trials

Explore recruiting consolidation clinical trials.

Recruiting consolidation studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Consolidation trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An ALFA 2101 multicenter randomized phase II study: CPX-351 versus intensive chemotherapy in patients with de novo intermediate or adverse risk AML stratified by genomics

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase 3, open-label, controlled, randomized study of newly diagnosed multiple myeloma treatment, designed to evaluate the efficacy and safety of the elranatamab-lenalidomide combination as a replacement for chemotherapy followed by autologous stem cell transplant in the consolidation phase, and to compare elranatamab with standard of care in the maintenance phase (ElLen; IFM 2025-01)

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

PCL-2 - PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION (PCL-2 STUDY)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase 1/2 evaluating the addition of venetoclax to standard 3+7 and midostaurin induction treatment in patients with FLT3-mutated Acute Myeloid Leukemia eligible to intensive chemotherapy - MIDOVEN

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

IFCT-2501 IDEATION ctDNA-guIDEd consolidATION immunotherapy after chemoradiotherapy in patients with stage III non-small cell lung cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

EORTC 2029-LCG: Immunotherapy Consolidation After Radical treatment of de-novo Oligo-metaStatic NSCLC: ICARS

Spain, Belgium, France, Italy, Netherlands

Phase II and Phase III (Integrated) EU CTIS Study details

Consolidation trials by city

Consolidation in Toronto Consolidation in Vancouver Consolidation in Montreal Consolidation in Calgary Consolidation in Edmonton Consolidation in Ottawa Consolidation in Winnipeg Consolidation in Quebec City Consolidation in Hamilton Consolidation in Kitchener Consolidation in London Consolidation in Halifax Consolidation in New York Consolidation in Los Angeles Consolidation in Chicago Consolidation in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease